Diabetes-associated markers and methods of use thereof
Disclosed are methods of identifying subjects with Diabetes or a pre-diabetic condition, methods of identifying subjects at risk for developing Diabetes or a pre-diabetic condition, methods of differentially diagnosing diseases associated with Diabetes or a pre-diabetic condition from other diseases or within sub-classifications of Diabetes, methods of evaluating the risk of progression to Diabetes or a pre-diabetic condition in patients, methods of evaluating the effectiveness of treatments in subjects with Diabetes or a pre-diabetic condition, and methods of selecting therapies for treating Diabetes or a pre-diabetic condition, using biomarkers.
1 . A method with a predetermined level of predictability for assessing a risk of development of Diabetes Mellitus or a pre-diabetic condition in a subject comprising:
a. measuring the level of an effective amount of two or more DBRISKMARKERS selected from the group consisting of DBRISKMARKERS1-260 in a sample from the subject, and
b. measuring a clinically significant alteration in the level of the two or more DBRISKMARKERS in the sample, wherein the alteration indicates an increased risk of developing Diabetes Mellitus or a pre-diabetic condition in the subject.
2 . The method of claim 1 , wherein the Diabetes Mellitus comprises Type 1 Diabetes, Type 2 Diabetes, or gestational Diabetes.
3 . The method of claim 1 , wherein the pre-diabetic condition comprises IFG, IGT, Metabolic Syndrome, or Syndrome X.
4 . The method of claim 1 , wherein the level of DBRISKMARKERS is measured electrophoretically or immunochemically.
5 . The method of claim 4 , wherein the immunochemical detection is by radioimmunoassay, immunofluorescence assay or by an enzyme-linked immunosorbent assay.
6 . The method of claim 1 , wherein the subject has not been previously diagnosed or identified as having the Diabetes Mellitus or the pre-diabetic condition.
7 . The method of claim 1 , wherein the subject is asymptomatic for the Diabetes Mellitus or the pre-diabetic condition.
8 . The method of claim 1 , wherein the sample is serum, blood plasma, blood cells, endothelial cells, tissue biopsies, ascites fluid, bone marrow, interstitial fluid, sputum, or urine.
9 . The method of claim 1 , wherein the level of expression of five or more DBRISKMARKERS is measured.
10 . The method of claim 1 , wherein the level of expression of ten or more DBRISKMARKERS is measured.
11 . The method of claim 1 , wherein the level of expression of twenty-five or more DBRISKMARKERS is measured.
12 . The method of claim 1 , wherein the level of expression of fifty or more DBRISKMARKERS is measured.
13 . A method with a predetermined level of predictability for diagnosing or identifying a subject having Diabetes Mellitus or a pre-diabetic condition comprising:
a. measuring the level of an effective amount of two or more DBRISKMARKERS selected from the group consisting of DBRISKMARKERS1-260 in a sample from the subject, and
b. comparing the level of the effective amount of the two or more DBRISKMARKERS to a reference value.
14 . The method of claim 13 , wherein the Diabetes Mellitus comprises Type 1 Diabetes, Type 2 Diabetes, or gestational Diabetes.
15 . The method of claim 13 , wherein the pre-diabetic condition comprises IFG, IGT, Metabolic Syndrome, or Syndrome X.
16 . The method of claim 13 , wherein the reference value is an index value.
17 . The method of claim 13 , wherein the reference value is derived from one or more risk prediction algorithms or computed indices for the Diabetes or pre-diabetic condition.
18 . The method of claim 13 , wherein the sample is serum, blood plasma, blood cells, endothelial cells, tissue biopsies, ascites fluid, bone marrow, interstitial fluid, sputum, or urine.
19 . A method with a predetermined level of predictability for assessing a risk of impaired glucose tolerance in a subject comprising:
a. measuring the level of an effective amount of two or more DBRISKMARKERS selected from the group consisting of DBRISKMARKERS1-260 in a sample from the subject, and
b. measuring a clinically significant alteration in the level of the two or more DBRISKMARKERS in the sample, wherein the alteration indicates an increased risk of impaired glucose tolerance in the subject.
20 . The method of claim 19 , wherein the level of DBRISKMARKERS is measured electrophoretically or immunochemically.
21 . The method of claim 19 , wherein the level of DBRISKMARKERS is measured by specific oligonucleotide hybridization.
22 . The method of claim 20 , wherein the immunochemical detection is by radio-immunoassay, immunofluorescence assay or by an enzyme-linked immunosorbent assay.
23 . The method of claim 19 , wherein the subject has not been previously diagnosed as having impaired glucose tolerance.
24 . The method of claim 19 , wherein the subject is asymptomatic for the impaired glucose tolerance.
25 . The method of claim 19 , wherein the sample is serum, blood plasma, blood cells, endothelial cells, tissue biopsies, ascites fluid, bone marrow, interstitial fluid, sputum, or urine.
26 . The method of claim 19 , wherein the level of expression of five or more DBRISKMARKERS is measured.
27 . The method of claim 19 , wherein the level of expression of ten or more DBRISKMARKERS is measured.
28 . The method of claim 19 , wherein the level of expression of twenty-five or more DBRISKMARKERS is measured.
29 . The method of claim 19 , wherein the level of expression of fifty or more DBRISKMARKERS is measured.
30 . A method with a predetermined level of predictability for diagnosing or identifying a subject having impaired glucose tolerance comprising:
a. measuring the level of an effective amount of two or more DBRISKMARKERS selected from the group consisting of DBRISKMARKERS1-260 in a sample from the subject, and
b. comparing the level of the effective amount of the two or more DBRISKMARKERS to a reference value.
31 . The method of claim 30 , wherein the sample is serum, blood plasma, blood cells, endothelial cells, tissue biopsies, ascites fluid, bone marrow, interstitial fluid, sputum, or urine.
32 . The method of claim 30 , wherein the reference value is an index value.
33 . The method of claim 30 , wherein the reference value is derived from one or more risk prediction algorithms or computed indices for impaired glucose tolerance.
34 . A method with a predetermined level of predictability for assessing the progression of Diabetes Mellitus or a pre-diabetic condition in a subject, comprising:
a. detecting the level of an effective amount of two or more DBRISKMARKERS selected from the group consisting of DBRISKMARKERS1-260 in a first sample from the subject at a first period of time;
b. detecting the level of an effective amount of two or more DBRISKMARKERS in a second sample from the subject at a second period of time;
c. comparing the level of the effective amount of the two or more DBRISKMARKERS detected in step (a) to the amount detected in step (b), or to a reference value.
35 . The method of claim 34 , wherein the Diabetes Mellitus comprises Type 1 Diabetes, Type 2 Diabetes, or gestational Diabetes.
36 . The method of claim 34 , wherein the pre-diabetic condition comprises IFG, IGT, Metabolic Syndrome, or Syndrome X.
37 . The method of claim 34 , wherein the subject has previously been diagnosed or identified as suffering from the Diabetes Mellitus or the pre-diabetic condition.
38 . The method of claim 34 , wherein the subject has previously been treated for the Diabetes Mellitus or the pre-diabetic condition.
39 . The method of claim 34 , wherein the subject has not been previously diagnosed or identified as suffering from the Diabetes Mellitus or the pre-diabetic condition.
40 . The method of claim 34 , wherein the subject is asymptomatic for the Diabetes Mellitus or the pre-diabetic condition.
41 . The method of claim 34 , wherein the first sample is taken from the subject prior to being treated for the Diabetes Mellitus or the pre-diabetic condition.
42 . The method of claim 34 , wherein the second sample is taken from the subject after being treated for the Diabetes Mellitus or the pre-diabetic condition.
43 . The method of claim 34 , wherein the reference value is derived from one or more subjects who have suffered from Diabetes Mellitus or a pre-diabetic condition.
44 . A method with a predetermined level of predictability for assessing the progression of impaired glucose tolerance associated with Diabetes Mellitus or a pre-diabetic condition in a subject comprising:
a. detecting the level of an effective amount of two or more DBRISKMARKERS selected from the group consisting of DBRISKMARKERS1-260 in a first sample from the subject at a first period of time;
b. detecting the level of an effective amount of two or more DBRISKMARKERS in a second sample from the subject at a second period of time;
c. comparing the level of the effective amount of the two or more DBRISKMARKERS detected in step (a) to the amount detected in step (b), or to a reference value.
45 . The method of claim 44 , wherein the subject is suffering from the Diabetes Mellitus or the pre-diabetic condition.
46 . The method of claim 44 , wherein the subject has previously been treated for the Diabetes Mellitus or the pre-diabetic condition.
47 . The method of claim 44 , wherein the subject has not been previously diagnosed or identified as having impaired glucose tolerance or suffering from the Diabetes Mellitus or the pre-diabetic condition.
48 . The method of claim 44 , wherein the subject is asymptomatic for the impaired glucose tolerance, or is asymptomatic for the Diabetes Mellitus or the pre-diabetic condition.
49 . The method of claim 44 , wherein the first sample is taken from the subject prior to being treated for the impaired glucose tolerance, Diabetes Mellitus, or the pre-diabetic condition.
50 . The method of claim 44 , wherein the second sample is taken from the subject after being treated for the impaired glucose tolerance, Diabetes Mellitus, or the pre-diabetic condition.
51 . The method of claim 44 , wherein the reference value is derived from one or more subjects who have suffered from impaired glucose tolerance, Diabetes Mellitus, or a pre-diabetic condition.
52 . A method with a predetermined level of predictability for monitoring the effectiveness of treatment for Diabetes Mellitus or a pre-diabetic condition comprising:
a. detecting the level of an effective amount of two or more DBRISKMARKERS selected from the group consisting of DBRISKMARKERS1-260 in a first sample from the subject at a first period of time;
b. detecting the level of an effective amount of two or more DBRISKMARKERS in a second sample from the subject at a second period of time;
c. comparing the level of the effective amount of the two or more DBRISKMARKERS detected in step (a) to the amount detected in step (b), or to a reference value, wherein the effectiveness of treatment is monitored by a change in the level of the effective amount of two or more DBRISKMARKERS from the subject.
53 . The method of claim 52 , wherein the Diabetes Mellitus comprises Type 1 Diabetes, Type 2 Diabetes, or gestational Diabetes.
54 . The method of claim 52 , wherein the pre-diabetic condition comprises IFG, IGT, Metabolic Syndrome, or Syndrome X.
55 . The method of claim 52 , wherein the subject is suffering from the Diabetes Mellitus or the pre-diabetic condition.
56 . The method of claim 52 , wherein the subject has previously been treated for the Diabetes Mellitus or the pre-diabetic condition.
57 . The method of claim 52 , wherein the first sample is taken from the subject prior to being treated for the Diabetes Mellitus or the pre-diabetic condition.
58 . The method of claim 52 , wherein the second sample is taken from the subject after being treated for the Diabetes Mellitus or the pre-diabetic condition.
59 . The method of claim 52 , wherein the treatment for the Diabetes Mellitus or the pre-diabetic condition comprises exercise regimens, dietary supplements, therapeutic agents, surgical intervention, and prophylactic agents.
60 . The method of claim 52 , wherein the reference value is derived from one or more subjects who show an improvement in Diabetes risk factors as a result of one or more treatments for the Diabetes Mellitus or the pre-diabetic condition.
61 . The method of claim 52 , wherein the effectiveness of treatment is additionally monitored by detecting changes in body mass index (BMI), insulin levels, blood glucose levels, HDL levels, systolic and/or diastolic blood pressure, or combinations thereof.
62 . The method of claim 61 , wherein changes in blood glucose levels are detected by an oral glucose tolerance test.
63 . A method with a predetermined level of predictability for selecting a treatment regimen for a subject diagnosed with or at risk for Diabetes Mellitus or a pre-diabetic condition comprising:
a. detecting the level of an effective amount of two or more DBRISKMARKERS selected from the group consisting of DBRISKMARKERS1-260 in a first sample from the subject at a first period of time;
b. optionally detecting the level of an effective amount of two or more DBRISKMARKERS in a second sample from the subject at a second period of time;
c. comparing the level of the effective amount of the two or more DBRISKMARKERS detected in step (a) to a reference value, or optionally, to the amount detected in step (b).
64 . The method of claim 63 , wherein the Diabetes Mellitus comprises Type 1 Diabetes, Type 2 Diabetes, or gestational Diabetes.
65 . The method of claim 63 , wherein the pre-diabetic condition comprises IFG, IGT, Metabolic Syndrome, or Syndrome X.
66 . The method of claim 63 , wherein the subject is suffering from the Diabetes Mellitus or the pre-diabetic condition.
67 . The method of claim 63 , wherein the subject has previously been treated for the Diabetes Mellitus or the pre-diabetic condition.
68 . The method of claim 63 , wherein the subject has not been previously diagnosed or identified as suffering from Diabetes Mellitus or the pre-diabetic condition.
69 . The method of claim 63 , wherein the first sample is taken from the subject prior to being treated for the Diabetes Mellitus or the pre-diabetic condition.
70 . The method of claim 63 , wherein the second sample is taken from the subject after being treated for the Diabetes Mellitus or the pre-diabetic condition.
71 . The method of claim 63 , wherein the treatment for the Diabetes Mellitus or the pre-diabetic condition comprises exercise regimens, dietary supplements, therapeutic agents, surgical intervention, and prophylactic agents.
72 . The method of claim 63 , wherein the reference value is derived from one or more subjects who show an improvement in Diabetes risk factors as a result of one or more treatments for the Diabetes Mellitus or the pre-diabetic condition.
73 . The method of claim 72 , wherein the improvement is monitored by detecting a reduction in body mass index (BMI), a reduction in blood glucose levels, an increase in insulin levels, an increase in HDL levels, a reduction in systolic and/or diastolic blood pressure, or combinations thereof.
74 . The method of claim 73 , wherein the reduction in blood glucose levels is measured by oral glucose tolerance test.
75 . A Diabetes Mellitus reference expression profile, comprising a pattern of marker levels of an effective amount of two or more markers selected from the group consisting of DBRISKMARKERS1-260, taken from one or more subjects who do not have the Diabetes Mellitus.
76 . The profile of claim 75 , wherein the Diabetes Mellitus comprises Type 1 Diabetes, Type 2 Diabetes, or gestational Diabetes.
77 . An impaired glucose tolerance reference expression profile, comprising a pattern of marker levels of an effective amount of two or more markers selected from the group consisting of DBRISKMARKERS1-260, taken from one or more subjects who do not have impaired glucose tolerance.
78 . A Diabetes Mellitus subject expression profile, comprising a pattern of marker levels of an effective amount of two or more markers selected from the group consisting of DBRISKMARKERS1-260 taken from one or more subjects who have the Diabetes Mellitus, are at risk for developing the Diabetes Mellitus, or are being treated for the Diabetes Mellitus.
79 . The profile of claim 78 , wherein the Diabetes Mellitus comprises Type 1 Diabetes, Type 2 Diabetes, or gestational Diabetes.
80 . An impaired glucose tolerance subject expression profile, comprising a pattern of marker levels of an effective amount of two or more markers selected from the group consisting of DBRISKMARKERS1-260 taken from one or more subjects who have impaired glucose tolerance, are at risk for developing impaired glucose tolerance, or are being treated for impaired glucose tolerance.
81 . A kit comprising a plurality of DBRISKMARKER detection reagents that detect the corresponding DBRISKMARKERS selected from the group consisting of DBRISKMARKERS1-260, sufficient to generate the profiles of claims 75 , 77 , 78 , or 80 .
82 . The kit of claim 81 , wherein the detection reagent comprises one or more antibodies or fragments thereof.
83 . The kit of claim 81 , wherein the detection reagent comprises one or more oligonucleotides.
84 . The kit of claim 81 , wherein the detection reagent comprises one or more aptamers.
85 . A machine readable media containing one or more Diabetes Mellitus reference expression profiles according to claim 75 , or one or more Diabetes Mellitus subject expression profiles according to claim 78 , and optionally, additional test results and subject information.
86 . A machine readable media containing one or more impaired glucose tolerance reference expression profiles according to claim 77 , or one or more impaired glucose tolerance subject expression profiles according to claim 80 , and optionally, additional test results and subject information.
87 . A DBRISKMARKER panel comprising one or more DBRISKMARKERS that are indicative of a physiological or biochemical pathway associated with Diabetes Mellitus or a pre-diabetic condition.
88 . The panel of claim 87 , wherein the physiological or biochemical pathway comprises autoimmune regulation, inflammation and endothelial function, focal adhesions, leukocyte transendothelial migration, natural killer cell mediated cytotoxicity, regulation of the actin cytoskeleton, adherens/tight/gap junctions, and extracellular matrix-receptor interaction, adipocyte development and maintenance, hematopoietic cell lineage, complement and coagulation cascades, intra- and extracellular cell signaling pathways.
89 . The panel of claim 87 , wherein the Diabetes Mellitus comprises Type 1 Diabetes, Type 2 Diabetes, or gestational Diabetes.
90 . The panel of claim 87 , wherein the pre-diabetic condition comprises IFG, IGT, Metabolic Syndrome, or Syndrome X.
91 . A DBRISKMARKER panel comprising one or more DBRISKMARKERS that are indicative of a site associated with Diabetes Mellitus or a pre-diabetic condition.
92 . The panel of claim 90 , wherein the site comprises beta cells, endothelial cells, skeletal and smooth muscle, or peripheral, cardiovascular, or cerebrovascular arteries.
93 . The panel of claim 90 , wherein the Diabetes Mellitus comprises Type 1 Diabetes, Type 2 Diabetes, or gestational Diabetes.
94 . The panel of claim 90 , wherein the pre-diabetic condition comprises IFG, IGT, Metabolic Syndrome, or Syndrome X.
95 . A DBRISKMARKER panel comprising one or more DBRISKMARKERS that are indicative of the progression of Diabetes Mellitus or a pre-diabetic condition.
96 . The panel of claim 95 , wherein the Diabetes Mellitus comprises Type 1 Diabetes, Type 2 Diabetes, or gestational Diabetes.
97 . The panel of claim 95 , wherein the pre-diabetic condition comprises IFG, IGT, Metabolic Syndrome, or Syndrome X.
98 . A DBRISKMARKER panel comprising one or more DBRISKMARKERS that are indicative of the speed of progression of Diabetes Mellitus or a pre-diabetic condition.
99 . The panel of claim 98 , wherein the Diabetes Mellitus comprises Type 1 Diabetes, Type 2 Diabetes, or gestational Diabetes.
100 . The panel of claim 98 , wherein the pre-diabetic condition comprises IFG, IGT, Metabolic Syndrome, or Syndrome X.
101 . A DBRISKMARKER panel comprising one or more DBRISKMARKERS that are specific to one or more types of Diabetes Mellitus.
102 . The panel of claim 101 , wherein the Diabetes Mellitus comprises Type 1 Diabetes, Type 2 Diabetes, or gestational Diabetes.
103 . A DBRISKMARKER panel comprising one or more DBRISKMARKERS that are specific to a pre-diabetic condition.
104 . The panel of claim 103 , wherein the pre-diabetic condition comprises IFG, IGT, Metabolic Syndrome, or Syndrome X.
105 . A DBRISKMARKER panel comprising two or more DBRISKMARKERS selected from the group consisting of: Leptin (LEP), Haptoglobin (HP), Insulin-like growth factor binding protein 3 (ILGFBP3), Resistin (RETN), Matrix Metallopeptidase 2 (MMP-2), Angiotensin I converting enzyme (peptidyl dipeptidase A)-1 (ACE), complement component 4A (C4A), CD14 molecule (CD14), selectin E (SELE), colony stimulating factor 1 (macrophage; CSF1), and vascular endothelial growth factor (VEGF), c-reactive protein (pentraxin-related; CRP), Tumor Necrosis Factor Receptor Superfamily Member 1A (TNFRSF1A), RAGE (Advanced Glycosylation End Product-specific Receptor [AGER]), and CD26 (dipeptidyl peptidase 4; DPP4).
106 . A method for treating one or more subjects at risk for developing Diabetes Mellitus or a pre-diabetic condition, comprising:
a. detecting the presence of increased levels of at least two different DBRISKMARKERS present in a sample from the one or more subjects; and
b. treating the one or more subjects with one or more Diabetes-modulating drugs until altered levels of the at least two different DBRISKMARKERS return to a baseline value measured in one or more subjects at low risk for developing the Diabetes Mellitus or the pre-diabetic condition, or a baseline value measured in one or more subjects who show improvements in Diabetes risk markers as a result of treatment with one or more Diabetes-modulating drugs.
107 . The method of claim 105 , wherein the Diabetes Mellitus comprises Type 1 Diabetes, Type 2 Diabetes, or gestational Diabetes.
108 . The method of claim 105 , wherein the pre-diabetic condition comprises IFG, IGT, Metabolic Syndrome, or Syndrome X.
109 . The method of claim 105 , wherein the Diabetes-modulating drugs comprise sulfonylureas; biguanides; insulin, insulin analogs; peroximsome proliferator-activated receptor-γ (PPAR-γ) agonists; dual-acting PPAR agonists; insulin secretagogues; analogs of glucagon-like peptide-1 (GLP-1); inhibitors of dipeptidyl peptidase IV; pancreatic lipase inhibitors; α-glucosidase inhibitors; and combinations thereof.
110 . The method of claim 105 , wherein the improvements in Diabetes risk markers as a result of treatment with one or more Diabetes-modulating drugs comprise a reduction in body mass index (BMI), a reduction in blood glucose levels, an increase in insulin levels, an increase in HDL levels, a reduction in systolic and/or diastolic blood pressure, or combinations thereof.
111 . A method of evaluating changes in the risk of impaired glucose tolerance in a subject diagnosed with or at risk for developing a pre-diabetic condition, comprising:
a. detecting the level of an effective amount of two or more DBRISKMARKERS selected from the group consisting of DBRISKMARKERS1-260 in a first sample from the subject at a first period of time;
b. optionally detecting the level of an effective amount of two or more DBRISKMARKERS in a second sample from the subject at a second period of time;
c. comparing the level of the effective amount of the two or more DBRISKMARKERS detected in step (a) to a reference value, or optionally, the amount in step (b).
112 . The method of claim 110 , wherein the pre-diabetic condition comprises IFG, IGT, Metabolic Syndrome, or Syndrome X.
113 . The method of claim 110 , wherein the subject is suffering from the pre-diabetic condition.
114 . The method of claim 110 , wherein the subject has previously been treated for the pre-diabetic condition.
115 . The method of claim 110 , wherein the subject has not been previously diagnosed or identified as suffering from the pre-diabetic condition.
116 . The method of claim 110 , wherein the subject is asymptomatic for the pre-diabetic condition.
117 . The method of claim 110 , wherein the first sample is taken from the subject prior to being treated for the pre-diabetic condition.
118 . The method of claim 110 , wherein the second sample is taken from the subject after being treated for the pre-diabetic condition.
119 . The method of claim 110 , wherein the treatment for the pre-diabetic condition comprises exercise regimens, dietary supplements, therapeutic agents, surgical intervention, and prophylactic agents.
120 . The method of claim 110 , wherein the reference value is derived from one or more subjects who have suffered from impaired glucose tolerance.
121 . A method of differentially diagnosing disease states associated with Diabetes Mellitus or a pre-diabetic condition in a subject comprising:
a. detecting the level of an effective amount of two or more DBRISKMARKERS selected from the group consisting of DBRISKMARKERS1-260 in a sample from the subject; and
b. comparing the level of the effective amount of the two or more DBORISKMARKERS detected in step (a) to the Diabetes Mellitus disease subject expression profile of claim 78 , to the impaired glucose tolerance subject expression profile of claim 80 , or to a reference value.
122 . The method of claim 120 , wherein the Diabetes Mellitus comprises Type 1 Diabetes, Type 2 Diabetes, or gestational Diabetes.
123 . The method of claim 120 , wherein the pre-diabetic condition comprises IFG, IGT, Metabolic Syndrome, or Syndrome X.
124 . The method of claim 120 , wherein the subject has not previously been diagnosed or identified as suffering from the Diabetes Mellitus or the pre-diabetic condition.
125 . The method of claim 120 , wherein the subject has not been previously treated for the Diabetes Mellitus or the pre-diabetic condition.
126 . The method of claim 120 , wherein the subject has been previously treated for the Diabetes Mellitus or the pre-diabetic condition.
127 . The method of claim 120 , wherein the subject is asymptomatic for the Diabetes Mellitus or the pre-diabetic condition.
128 . In a method of diagnosing or identifying a subject at risk for developing Diabetes or a pre-diabetic condition by analyzing Diabetes risk factors, the improvement comprising:
a. measuring the level of an effective amount of two or more DBRISKMARKERS selected from the group consisting of DBRISKMARKERS1-260 in a sample from the subject, and
b. measuring a clinically significant alteration in the level of the two or more DBRISKMARKERS in the sample, wherein the alteration indicates an increased risk of developing Diabetes Mellitus or a pre-diabetic condition in the subject.
129 . In a method of diagnosing or identifying a subject at risk for developing Diabetes or a pre-diabetic condition by analyzing Diabetes risk factors, the improvement comprising:
a. measuring the level of an effective amount of one or more DBRISKMARKERS selected from the group consisting of: Leptin (LEP), Haptoglobin (HP), Insulin-like growth factor binding protein 3 (ILGFBP3), Resistin (RETN), Matrix Metallopeptidase 2 (MMP-2), Angiotensin I converting enzyme (peptidyl dipeptidase A)-1 (ACE), complement component 4A (C4A), CD14 molecule (CD14), selectin E (SELE), colony stimulating factor 1 (macrophage; CSF1), and vascular endothelial growth factor (VEGF), c-reactive protein (pentraxin-related; CRP), Tumor Necrosis Factor Receptor Superfamily Member 1A (TNFRSF 1A), RAGE (Advanced Glycosylation End Product-specific Receptor [AGER]), and CD26 (dipeptidyl peptidase 4; DPP4), and
b. measuring a clinically significant alteration in the level of the one or more DBRISKMARKERS in the sample, wherein the alteration indicates an increased risk of developing Diabetes Mellitus or a pre-diabetic condition in the subject.
130 . In a method of diagnosing or identifying a subject at risk for developing Diabetes or a pre-diabetic condition by analyzing Diabetes risk factors, the improvement comprising:
a. measuring the level of an effective amount of two or more DBRISKMARKERS selected from the group consisting of: Leptin (LEP), Haptoglobin (HP), Insulin-like growth factor binding protein 3 (ILGFBP3), Resistin (RETN), Matrix Metallopeptidase 2 (MMP-2), Angiotensin I converting enzyme (peptidyl dipeptidase A)-1 (ACE), complement component 4A (C4A), CD14 molecule (CD14), selectin E (SELE), colony stimulating factor 1 (macrophage; CSF1), and vascular endothelial growth factor (VEGF), c-reactive protein (pentraxin-related; CRP), Tumor Necrosis Factor Receptor Superfamily Member 1A (TNFRSF 1A), RAGE (Advanced Glycosylation End Product-specific Receptor [AGER]), and CD26 (dipeptidyl peptidase 4; DPP4), and
b. measuring a clinically significant alteration in the level of the two or more DBRISKMARKERS in the sample, wherein the alteration indicates an increased risk of developing Diabetes Mellitus or a pre-diabetic condition in the subject.